Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer /Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Panjiayuan South Lane, Chaoyang District, Beijing, 100021, People's Republic of China.
Cancer Registry Office, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Qual Life Res. 2021 Mar;30(3):841-854. doi: 10.1007/s11136-020-02636-w. Epub 2020 Sep 15.
To compare the performance of three-level EuroQol five-dimensions (EQ-5D-3L) and five-level EuroQol five-dimensions (EQ-5D-5L) among common cancer patients in urban China.
A hospital-based cross-sectional survey was conducted in three provinces from 2016 to 2018 in urban China. Patients with breast cancer, colorectal cancer, or lung cancer were recruited to complete the EQ-5D-3L and EQ-5D-5L questionnaires. Response distribution, discriminatory power (indicator: Shannon index [H'] and Shannon evenness index [J']), ceiling effect (the proportion of full health state), convergent validity, and health-related quality of life (HRQoL) were compared between the two instruments.
A total of 1802 cancer patients (breast cancer: 601, colorectal cancer: 601, lung cancer: 600) were included, with the mean age of 55.6 years. The average inconsistency rate was 4.4%. Compared with EQ-5D-3L (average: H' = 1.100, J' = 0.696), an improved discriminatory power was observed in EQ-5D-5L (H' = 1.473, J' = 0.932), especially contributing to anxiety/depression dimensions. The ceiling effect was diminished in EQ-5D-5L (26.5%) in comparison with EQ-5D-3L (34.5%) (p < 0.001), mainly reflected in the pain/discomfort and anxiety/depression dimensions. The overall utility score was 0.790 (95% CI 0.778-0.801) for EQ-5D-3L and 0.803 (0.790-0.816) for EQ-5D-5L (p < 0.001). A similar pattern was also observed in the detailed cancer-specific analysis.
With greater discriminatory power, convergent validity and lower ceiling, EQ-5D-5L may be preferable to EQ-5D-3L for the assessment of HRQoL among cancer patients. However, higher utility scores derived form EQ-5D-5L may also lead to lower QALY gains than those of 3L potentially in cost-utility studies and underestimation in the burden of disease.
比较三级欧洲五维健康量表(EQ-5D-3L)和五级欧洲五维健康量表(EQ-5D-5L)在中国城市常见癌症患者中的表现。
2016 年至 2018 年在中国三个省份进行了一项基于医院的横断面调查。招募乳腺癌、结直肠癌或肺癌患者完成 EQ-5D-3L 和 EQ-5D-5L 问卷。比较两种工具的反应分布、区分能力(指标:香农指数[H']和香农均匀度指数[J'])、天花板效应(完全健康状态的比例)、收敛效度和健康相关生活质量(HRQoL)。
共纳入 1802 例癌症患者(乳腺癌 601 例、结直肠癌 601 例、肺癌 600 例),平均年龄为 55.6 岁。平均不一致率为 4.4%。与 EQ-5D-3L(平均:H'=1.100,J'=0.696)相比,EQ-5D-5L 具有更好的区分能力(H'=1.473,J'=0.932),特别是对焦虑/抑郁维度有贡献。与 EQ-5D-3L(26.5%)相比,EQ-5D-5L 的天花板效应降低(34.5%)(p<0.001),主要反映在疼痛/不适和焦虑/抑郁维度。EQ-5D-3L 的整体效用评分为 0.790(95%CI 0.778-0.801),EQ-5D-5L 为 0.803(0.790-0.816)(p<0.001)。在详细的癌症特异性分析中也观察到类似的模式。
EQ-5D-5L 具有更好的区分能力、收敛效度和更低的天花板效应,用于评估癌症患者的 HRQoL 可能优于 EQ-5D-3L。然而,EQ-5D-5L 得出的更高效用评分可能导致成本效用研究中的 QALY 增益低于 3L,并且可能低估疾病负担。